

### Higher forex gains aids 1Q, margin sustenance to drive re-rating

Ajanta's Q1 missed our estimates by 5%/15% on top-line and PAT (adjusted for forex gain of Rs250mn). EBITDA margins at 29.4% contracted 480 bps QoQ despite 77% gross margins as cost structures normalized in Q1. Revenue grew 13% YoY, driven by strong recovery in India (32% YoY). Field force rationalization aided in productivity. Exports performance was muted at 6% YoY growth with US steady at US\$23mn (lack of major launch), branded business up 8% YoY. Tender business declined owing to its lumpy nature. Management remained confident of outperforming market growth of its major geographies (India, Asia and Africa) and maintaining EBITDA margins at 29-30% for FY22E. With most levers of cost control exhausted, the margin performance will now be driven by higher revenue growth.

**Key triggers:** (1) India business to outperform IPM by 2-3% (2) US achieved breakeven in FY19 and is expected to drive operating leverage benefits with new launches (3) High exposure to branded business (70%) offers good growth visibility with superior margins (4) Margins to sustain at ~30% (5) Capex cycle done, expect improved A/O of 1.8-2x resulting in operating leverage, core RoCE expansion from 29% in FY20 to 39% in FY23E.

**Our View:** After breaking even in the US in FY19 and realigning its Africa branded business, Ajanta has consistently registered growth across market segments. 2HFY21 highlights the recovery in its ophthal and derma portfolio in India, while Q1FY22 reflects ramp up in cardiac portfolio which is likely to drive low teens growth in FY22. Besides, Ajanta's gross block has increased 3x in past 5 years (invested Rs16bn in facilities through internal accruals), indicating better free cash generation going ahead. We reckon that peak capacity utilization at Guwahati and Dahej plants over the next 2 years could potentially add Rs12bn to revenues.

Despite higher capex, slowdown in businesses, company has consistently generated FCF, which speaks volumes about its strong business model. We estimate sales/PAT CAGR of 13%/12% over FY21-23E, along with a margins at 31-32%. At the CMP, Ajanta is trading at 25x its FY23E EPS. Given its strong return profile and healthy balance sheet, we value Ajanta at a premium vs its peers. Our SOTP methodology values Ajanta at Rs2,642 (implying PE of 28x FY23E).

#### Q1FY22 Result (Rs Mn)

Particulars	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)
Revenue	7,480	6,682	11.9	7,568	(1.2)
Total Expense	5,278	4,450	18.6	4,974	6.1
EBITDA	2,202	2,232	(1.3)	2,594	(15.1)
Depreciation	309	280	10.2	306	0.9
EBIT	1,893	1,952	(3.0)	2,288	(17.3)
Other Income	76	131	(41.8)	25	201.6
Interest	15	16	(7.4)	26	(41.0)
EBT	2,205	2,067	6.7	2,288	(3.6)
Tax	467	589	(20.8)	695	(32.8)
RPAT	1,738	1,478	17.6	1,593	9.1
APAT	1,488	1,478	0.7	1,593	(6.6)
			(bps)		(bps)
Gross Margin (%)	77.1	77.1	(4)	77.8	(76)
EBITDA Margin (%)	29.4	33.4	(397)	34.3	(484)
NPM (%)	23.2	22.1	112	21.0	219
Tax Rate (%)	21.2	28.5	(733)	30.4	(920)
EBIT Margin (%)	25.3	29.2	(390)	30.2	(492)

CMP	Rs 2,395
Target / Upside	Rs 2,642 / 10%
NIFTY	15,779

#### Scrip Details

Equity / FV	Rs 174mn / Rs 2
Market Cap	Rs 208bn
	USD 3bn
52-week High/Low	Rs 2,435/ 1,425
Avg. Volume (no)	124,185
Bloom Code	AJP IN

Price Performance	1M	3M	12M
Absolute (%)	15	27	61
Rel to NIFTY (%)	15	21	22

#### Shareholding Pattern

	Dec'20	Mar'21	Jun'21
Promoters	70.3	70.3	70.3
MF/Banks/FIs	20.8	20.4	20.2
FIIIs	7.9	8.4	8.9
Public / Others	1.0	0.9	0.6

#### Valuation (x)

	FY21E	FY22E	FY23E
P/E	31.8	29.4	25.4
EV/EBITDA	20.5	19.4	16.4
ROE (%)	23.4	21.6	21.0
RoACE (%)	21.8	20.1	19.7

#### Estimates (Rs mn)

	FY21E	FY22E	FY23E
Revenue	28,897	32,815	37,034
EBITDA	9,986	10,273	11,825
PAT	6,539	7,070	8,194
EPS (Rs.)	75.2	81.3	94.2

**VP - Research: Sapna Jhawar**

Tel: +9122 40969724

E-mail: sapnaj@dolatcapital.com

**Associate: Zain Gulam Hussain**

Tel: +9122 40969725

E-mail: zain@dolatcapital.com

## Exhibit 1: Revenue Mix

Rs mn	Q1FY22	Q1FY21	YoY (%)	Q4FY21	QoQ (%)	FY22E	FY21	YoY (%)
Domestic Formulations	2,290	1,740	31.6	2,180	5.0	9,024	8,130	11.0
US	1,680	1,490	12.8	1,730	(2.9)	7,889	6,370	23.8
Africa branded	1,250	1,080	15.7	970	28.9	4,582	4,091	12.0
Africa Tender	540	620	(12.9)	800	(32.5)	2,846	2,710	5.0
Asia	1,650	1,610	2.5	1,760	(6.3)	8,007	7,149	12.0
Others	10	30	(66.7)	0	0	0	0	0
Gross revenues	7,420	6,570	12.9	7,440	(0.3)	32,347	28,450	13.7

Source: DART, Company

## Key con-call takeaways:

**India:** Branded formulations in Q1 reported 32% YoY growth on a lower base, price hikes in select products and 5 new launches (including 1 FTM).

- Management guided for additional 5-6 launches in 9M.
- Revival in the cardiac segment at 14% vs IPM growth of 15%, Pain segment grew 30% YoY vs IPM of 10% coupled with improving offtake of derma products (21% growth vs IPM growth of 12%) as clinic footfalls increase has driven growth.
- Issues in derma (Melacare) and Opthal (Softdrops market shift towards MaxMoist) has now stabilized and these segments are expected to outperform branded formulations growth vs IPM.
- In-order to improve productivity, company has rationalized its field force by 200 MRs. The cumulative field force now stands at 2800 and MR productivity as on Q1 stands at 3.2mn PCPA. The sales force rationalization program is ongoing.
- Management guided to beat IPM growth for FY22E to be driven by marketing and customer connect initiatives.

**US:** Ajanta continue to report steady growth in the US at US\$23mn in 1Q (up 13% YoY, down 3% QoQ) as Ranitidine recall comes in base.

- The management reiterated its filing guidance of 10-12 and 4-5 launches in FY22E (2 launched in Q1).
- Given that FY20 and FY21 had lower filings, we expect the product launch rate to also be at the lower end instead of usual run-rate of 6-8 launches.
- R&D guided to remain at 6% of sales in FY22E
- We expect the US business to grow 22% sales CAGR over FY21-23E, led by new launches and a lower base. US is profitable at the net level and new launches are expected to drive operating leverage. Key products filed are Chantix, Vimovo, Bystolic whose patents are set to expire in the near term.
- On a cumulative basis, Ajanta has 43 approvals, and 15 products pending for approval. It has already commercialized 38 products until now.

**Branded EM:** The EM branded business reported 8% YoY and 6% QoQ in Q1FY22.

- Management stated that activities in these markets have reached normalcy and guided of beating market growth across geographies.
- As on Q1, EM has 1400+ products registered across 29 markets.

- Growth in Asia is expected to be driven by steady performance in Philippines, new launches and volume led, whereas Africa market is guided to grow in high single digit over the next 2 years.

**Africa tender:** The tender business declined 13% YoY and 33% QoQ in Q1. We expect branded Africa business to report 9% CAGR, while the tender business is expected to grow at a modest 5% over FY21-23E.

**Capex:** Incurred Rs270mn capex in Q1, guided for Rs2bn for FY22E.

- Ajanta's Dahej facility, built with a capex of ~Rs4bn, is expected to ramp up from FY22E.
- Investment in Guwahati is Rs4bn. Its new ophthalmology block has started commercialization in 3QFY20. Management guided for asset turn of 1.5-2x for this unit.
- Current capacity utilization is ~60-70%
- Next 3 years, capex is expected to be largely maintenance capex.

### Profit and Loss Account

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
<b>Revenue</b>	<b>25,879</b>	<b>28,897</b>	<b>32,815</b>	<b>37,034</b>
<b>Total Expense</b>	<b>19,045</b>	<b>18,911</b>	<b>22,542</b>	<b>25,209</b>
COGS	6,557	6,451	8,124	8,892
Employees Cost	4,856	5,483	6,308	7,126
Other expenses	7,632	6,978	8,111	9,191
<b>EBIDTA</b>	<b>6,833</b>	<b>9,986</b>	<b>10,273</b>	<b>11,825</b>
Depreciation	957	1,161	1,326	1,444
<b>EBIT</b>	<b>5,876</b>	<b>8,825</b>	<b>8,947</b>	<b>10,380</b>
Interest	119	83	33	17
Other Income	922	260	268	278
Exc. / E.O. items	(39)	0	0	0
<b>EBT</b>	<b>6,640</b>	<b>9,002</b>	<b>9,182</b>	<b>10,642</b>
Tax	1,963	2,463	2,112	2,448
RPAT	4,677	6,539	7,070	8,194
Minority Interest	0	0	0	0
<b>Profit/Loss share of associates</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>APAT</b>	<b>4,677</b>	<b>6,539</b>	<b>7,070</b>	<b>8,194</b>

### Balance Sheet

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
<b>Sources of Funds</b>				
Equity Capital	175	174	174	174
Minority Interest	0	0	0	0
Reserves & Surplus	25,813	29,782	35,418	42,178
<b>Net Worth</b>	<b>25,989</b>	<b>29,956</b>	<b>35,592</b>	<b>42,352</b>
Total Debt	436	16	18	19
Net Deferred Tax Liability	1,897	2,551	2,685	2,832
<b>Total Capital Employed</b>	<b>28,321</b>	<b>32,524</b>	<b>38,295</b>	<b>45,203</b>

### Applications of Funds

Net Block	13,813	14,489	15,374	15,430
CWIP	2,227	2,004	2,304	2,604
Investments	181	139	174	218
<b>Current Assets, Loans &amp; Advances</b>	<b>16,966</b>	<b>21,155</b>	<b>24,859</b>	<b>32,747</b>
Inventories	4,957	7,665	5,597	7,263
Receivables	7,753	7,384	7,799	8,410
Cash and Bank Balances	2,053	2,096	7,311	12,764
Loans and Advances	669	1,018	1,159	1,319
Other Current Assets	863	1,235	1,235	1,235
<b>Less: Current Liabilities &amp; Provisions</b>	<b>4,866</b>	<b>5,264</b>	<b>4,416</b>	<b>5,796</b>
Payables	3,623	3,739	2,821	4,194
Other Current Liabilities	1,242	1,525	1,595	1,602
<i>sub total</i>				
Net Current Assets	12,100	15,891	20,443	26,951
<b>Total Assets</b>	<b>28,321</b>	<b>32,524</b>	<b>38,295</b>	<b>45,203</b>

E – Estimates

### Important Ratios

Particulars	FY20A	FY21E	FY22E	FY23E
<b>(A) Margins (%)</b>				
Gross Profit Margin	74.7	77.7	75.2	76.0
EBIDTA Margin	26.4	34.6	31.3	31.9
EBIT Margin	22.7	30.5	27.3	28.0
Tax rate	29.6	27.4	23.0	23.0
Net Profit Margin	18.1	22.6	21.5	22.1
<b>(B) As Percentage of Net Sales (%)</b>				
COGS	25.3	22.3	24.8	24.0
Employee	18.8	19.0	19.2	19.2
Other	29.5	24.1	24.7	24.8
<b>(C) Measure of Financial Status</b>				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	49.3	106.7	270.5	627.6
Inventory days	70	97	62	72
Debtors days	109	93	87	83
Average Cost of Debt	30.7	36.6	196.9	89.5
Payable days	51	47	31	41
Working Capital days	171	201	227	266
FA T/O	1.9	2.0	2.1	2.4
<b>(D) Measures of Investment</b>				
AEPS (Rs)	53.8	75.2	81.3	94.2
CEPS (Rs)	64.8	88.6	96.6	110.9
DPS (Rs)	13.3	9.5	16.5	16.5
Dividend Payout (%)	24.8	12.7	20.3	17.5
BVPS (Rs)	298.9	344.5	409.3	487.1
RoANW (%)	19.3	23.4	21.6	21.0
RoACE (%)	18.6	21.8	20.1	19.7
RoAIC (%)	24.0	31.1	29.1	32.7
<b>(E) Valuation Ratios</b>				
CMP (Rs)	2395	2395	2395	2395
P/E	44.5	31.8	29.4	25.4
Mcap (Rs Mn)	208,219	208,219	208,219	208,219
MCap/ Sales	8.0	7.2	6.3	5.6
EV	205,931	204,382	199,169	193,718
EV/Sales	8.0	7.1	6.1	5.2
EV/EBITDA	30.1	20.5	19.4	16.4
P/BV	8.0	7.0	5.9	4.9
Dividend Yield (%)	0.6	0.4	0.7	0.7
<b>(F) Growth Rate (%)</b>				
Revenue	25.9	11.7	13.6	12.9
EBITDA	20.6	46.1	2.9	15.1
EBIT	18.9	50.2	1.4	16.0
PBT	29.1	35.6	2.0	15.9
APAT	20.9	39.8	8.1	15.9
EPS	20.9	39.8	8.1	15.9

### Cash Flow

(Rs Mn)	FY20A	FY21E	FY22E	FY23E
CFO	4,670	5,708	9,226	8,744
CFI	(2,617)	(2,657)	(2,546)	(1,844)
CFF	(1,006)	(3,007)	(1,465)	(1,448)
FCFF	2,053	3,051	6,680	6,900
Opening Cash	1,005	2,053	2,096	7,311
Closing Cash	2,053	2,096	7,311	12,764


E – Estimates

### DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

### Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Aug-20	Accumulate	1,771	1,629
Nov-20	Accumulate	1,771	1,611
Feb-21	Buy	2,208	1,802
Feb-21	Buy	2,208	1,805
Apr-21	Buy	2,205	1,840

\*Price as on recommendation date

### DART Team

<b>Purvag Shah</b>	<b>Managing Director</b>	<b>purvag@dolatcapital.com</b>	<b>+9122 4096 9747</b>
--------------------	--------------------------	--------------------------------	------------------------

<b>Amit Khurana, CFA</b>	<b>Head of Equities</b>	<b>amit@dolatcapital.com</b>	<b>+9122 4096 9745</b>
--------------------------	-------------------------	------------------------------	------------------------

#### CONTACT DETAILS

Equity Sales	Designation	E-mail	Direct Lines
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735
Jubbin Shah	VP - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772
Anjana Jhaveri	VP - FII Sales	anjanaj@dolatcapital.com	+9122 4096 9758
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740
Equity Trading	Designation	E-mail	
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715
Dinesh Mehta	Co - Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705

**Dolat Capital Market Private Limited.**

Sunshine Tower, 28th Floor, Senapati Bapat Marg, Dadar (West), Mumbai 400013

---

**Analyst(s) Certification**

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

---

**I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)**

---

**II. Disclaimer:**

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

**For U.S. Entity/ persons only:** "This Report is considered independent third-party research and was prepared by Dolat Capital Market Private Limited, with headquarters in India. The distribution of this Research is provided pursuant to the exemption under Rule 15a-6(a) (2) and is only intended for an audience of Major U.S. Institutional Investors (MUSIIs) as defined by Rule 15a-6(b)(4). This research is not a product of StoneX Financial Inc. Dolat Capital Market Private Limited has sole control over the contents of this research report. StoneX Financial Inc. does not exercise any control over the contents of, or the views expressed in, any research reports prepared by Dolat Capital Market Private Limited and under Rule 15a-6(a) (3), any U.S. recipient of this research report wishing to affect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through StoneX Financial Inc. Please contact Paul Karrlsson-Willis at +1 (407) 741-5310 or email Paul.Karrlsson-Willis@stonex.com and/or Igor Chernomorskiy at +1 (212)379-5463 or email Igor.Chernomorskiy@stonex.com. Under no circumstances should any U.S. recipient of this research report effect any transaction to buy or sell securities or related financial instruments through the Dolat Capital Market Private Limited."



---

**Dolat Capital Market Private Limited.**

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000000685

Registered office: Unit no PO6-02A - PO6-02D, Tower A, WTC, Block 51, Zone-5, Road 5E, Gift City, Gandhinagar, Gujarat – 382355

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com

---